๐Ÿ‡บ๐Ÿ‡ธ FDA

Intelligence ยท Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors โ€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ€” searchable for business development and competitive intelligence.

280 results for โ€œLBโ€ Clear

  1. Palbociclib + Taselisib / Pictilisib

    United Therapeutics Europe Ltd

    Advanced Solid Tumours

    phase 1 small molecule completed

    1 trial

  2. Panobinostat (LBH589), Carboplatin and Paclitaxel

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  3. Satraplatin in combo with vinorelbine

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  4. Sodium phenylbutyrate

    ZEVRA THERAPEUTICS, INC.

    Combined D,L-2-hydroxyglutaric Aciduria

    phase 1 small molecule active

    1 trial

  5. TL011

    Teva Pharma GmbH

    DLBCL

    phase 1 mab completed

    1 trial

  6. This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body and if it can control the disease of people diagnosed with advanced cancer that has not responded to treatment, has returned after it has been treated, or cannot be treated by surgery, drugs, or any other known treatments.

    Celgene Europe Limited

    Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)

    phase 1 other active

    1 trial

  7. Vehicle to Methylprednisolone Aceponate Ointment, Methylprednisolone Aceponate Ointment, Advantanยฎ 0,1% Salbe

    Alphapharm Pty Ltd

    Mild to moderate atopic dermatitis

    phase 1 small molecule active

    1 trial

  8. Vemurafenib Oral Tablet [Zelboraf]

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

    phase 1 small molecule active

    1 trial

  9. bbT369

    Regeneron UK Limited

    Diffuse Large B Cell Lymphoma (DLBCL)

    phase 1 mab terminated

    1 trial

  10. ฮฑ-lactalbumin vaccine

    Anixa Biosciences Inc

    Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer

    phase 1 mab active

    1 trial

  11. 99mTc-Macro Albumin Aggregate

    BRIGHT MINDS BIOSCIENCES INC.

    Carcinoma

    approved small molecule completed

    1 trial

  12. Albendazole

    United Therapeutics Europe Ltd

    Ascariasis

    approved small molecule completed

    1 trial

  13. Albuterol eMDPI DS

    Teva Pharma GmbH

    Asthma

    approved small molecule completed

    1 trial

  14. Albuterol-HFA-MDI

    Teva Pharma GmbH

    Asthma

    approved small molecule completed

    1 trial

  15. Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method

    Takeda

    Hemophilia A

    approved mab completed

    4 trials

  16. BECLOMETASONE , FLUTICASONE , BUDESONIDE , SALBUTAMOL

    Disc Medicine

    Episodic expiratory wheezing

    approved small molecule active

    1 trial

  17. BLB-750 Vaccine (Qinghai RG strain)

    Takeda

    Pandemic Influenza Prevention

    approved mab completed

    1 trial

  18. Braftovi 50 mg hard capsules, Zelboraf 240 mg film-coated tablets, Encorafenib, Erbitux 5 mg/mL solution for infusion, PEMBROLIZUMAB, Braftovi 75 mg hard capsules, Braftovi 75 mg hard capsules, Braftovi 50 mg hard capsules, Ribociclib, Ribociclib, NIVOLUMAB, Mektovi 15 mg film-coated tablets, Mektovi 15 mg film-coated tablets, Ribociclib

    Pfizer Australia Pty Ltd

    Solid tumors

    approved small molecule active

    1 trial

  19. CARBOPLATIN, PACLITAXEL, DOCETAXEL, VINORELBINE TARTRATE, CISPLATIN, PEMETREXED

    CERO THERAPEUTICS HOLDINGS, INC.

    Completely resected stage I or IIA non-squamous non-small cell lung cancer (NSCLC)

    approved small molecule active

    1 trial

  20. HUMAN SERUM ALBUMIN, SODIUM CHLORIDE

    The George Institute

    descompensated hepatic cirrosis

    approved small molecule active

    1 trial

  21. Kerendia 20 mg film-coated tablets, Kerendia 10 mg film coated tablets, Jardiance 10 mg film-coated tablets

    Disc Medicine

    Albuminuria, Type 2 diabetes

    approved small molecule active

    1 trial

  22. SALBUTAMOL

    United Therapeutics Europe Ltd

    CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    approved small molecule completed

    1 trial

  23. Sodium Chloride Fresenius Kabi Italia 0.9 % Solution for infusion , DENOSUMAB, Sodium Fluoride (18F) Life Radiopharma 0,1 - 4 GBq/ml solution injectable

    Disc Medicine

    Fibrous dysplasia/McCune-Albright syndrome

    approved small molecule active

    1 trial

  24. Telbivudine treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Hepatitis B

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ€“3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources